person · Reporting owner

Gover Justin D.

Disclosed activity across 4 companies

Tapewire entity: 39300
SEC CIK: 0001754129

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
COMPASS Pathways plcCMPS · Entity 4567	Director	May 27, 2026	May 29, 2026
Design Therapeutics, Inc.DSGN · Entity 4991	Director	June 09, 2026	June 11, 2026
Xenon Pharmaceuticals Inc.XENE · Entity 2602	Director	June 01, 2026	June 04, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

COMPASS Pathways plc

Report date May 27, 2026 · Filed May 29, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.85 · Expires 2036-05-26	Direct	21,110	Reported balance After 2026-05-27 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-05-27 · Grant · Acquired 21,110 · Balance 21,110 F1: The shares underlying this option vest in full upon the earlier to occur of (i) the first anniversary of the date of grant or (ii) the date of COMPASS Pathways plc's Annual General Meeting of Shareholders in 2027. F2: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Filing footnotes · ownership attribution and instrument terms

F1: The shares underlying this option vest in full upon the earlier to occur of (i) the first anniversary of the date of grant or (ii) the date of COMPASS Pathways plc's Annual General Meeting of Shareholders in 2027.

F2: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Design Therapeutics, Inc.

Report date June 09, 2026 · Filed June 11, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.55 · Expires 2036-06-08	Direct	30,000	Reported balance After 2026-06-09 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-09 · Grant · Acquired 30,000 · Balance 30,000 F1: The shares subject to the option vest in equal monthly installments over 12 months following June 9, 2026 provided that the shares subject to the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to the option vest in equal monthly installments over 12 months following June 9, 2026 provided that the shares subject to the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders.

Xenon Pharmaceuticals Inc.

Report date June 01, 2026 · Filed June 04, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common SharesSEC Table I · non-derivative	Direct	2,645	Reported balance After 2026-06-01 transaction · row 1 1 source row Row 1 · 2026-06-01 · Exercise / conversion · Acquired 2,645 · Balance 2,645 F1: Represents Common Shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders.
Restricted Share UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-06-01 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-01 · Exercise / conversion · Disposed 2,645 · Balance 0 F1: Represents Common Shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders.
Restricted Share UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	1,593	Reported balance After 2026-06-03 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-06-03 · Grant · Acquired 1,593 · Balance 1,593 F3: Each RSU represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders.
Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $53.46 · Expires 2036-06-02	Direct	10,507	Reported balance After 2026-06-03 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-06-03 · Grant · Acquired 10,507 · Balance 10,507 F2: Vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders.

Filing footnotes · ownership attribution and instrument terms

F1: Represents Common Shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders.

F2: Vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders.

F3: Each RSU represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

GW PHARMACEUTICALS PLC

Report date May 05, 2021 · Filed May 07, 2021

Section 16 reporting ended · disclosed 2021-05-07. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	Reported balance After 2021-05-05 transaction · row 1 1 source row Row 1 · 2021-05-05 · Disposition to issuer · Disposed 222,773 · Balance 0 F1: On May 5, 2021, Jazz Pharmaceuticals Public Limited Company, a public limited company incorporated in the Republic of Ireland ("Jazz"), Jazz Pharmaceuticals UK Holdings Limited, a private limited company incorporated in England and Wales and an indirect wholly owned subsidiary of Jazz ("Bidco") and the DR Nominee (as defined in the Transaction Agreement) acquired all outstanding ordinary shares, par value British Pound Sterling 0.001 per share, of GW Pharmaceuticals plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement") (continued in footnote 2). F2: At the effective time of the Scheme of Arrangement, Scheme Shareholders (as defined in the Scheme of Arrangement) became entitled to receive for each Scheme Share (as defined in the Scheme of Arrangement) held by them an amount equal to $16.66 2/3 in cash plus 0.010030 ordinary shares, nominal value $0.0001 per share, of Jazz ("Jazz ordinary shares"). The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 15, 2021.
Ordinary SharesSEC Table I · non-derivative	IndirectBy Justin D. Gover 2020 Irrevocable Trust dated December 14, 2020	Reported balance After 2021-05-05 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2021-05-05 · Disposition to issuer · Disposed 456,048 · Balance 0 F1: On May 5, 2021, Jazz Pharmaceuticals Public Limited Company, a public limited company incorporated in the Republic of Ireland ("Jazz"), Jazz Pharmaceuticals UK Holdings Limited, a private limited company incorporated in England and Wales and an indirect wholly owned subsidiary of Jazz ("Bidco") and the DR Nominee (as defined in the Transaction Agreement) acquired all outstanding ordinary shares, par value British Pound Sterling 0.001 per share, of GW Pharmaceuticals plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement") (continued in footnote 2). F2: At the effective time of the Scheme of Arrangement, Scheme Shareholders (as defined in the Scheme of Arrangement) became entitled to receive for each Scheme Share (as defined in the Scheme of Arrangement) held by them an amount equal to $16.66 2/3 in cash plus 0.010030 ordinary shares, nominal value $0.0001 per share, of Jazz ("Jazz ordinary shares"). The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 15, 2021.
Ordinary SharesSEC Table I · non-derivative	IndirectBy the Gover Family Investment LLP	Reported balance After 2021-05-05 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2021-05-05 · Disposition to issuer · Disposed 1,867,308 · Balance 0 F1: On May 5, 2021, Jazz Pharmaceuticals Public Limited Company, a public limited company incorporated in the Republic of Ireland ("Jazz"), Jazz Pharmaceuticals UK Holdings Limited, a private limited company incorporated in England and Wales and an indirect wholly owned subsidiary of Jazz ("Bidco") and the DR Nominee (as defined in the Transaction Agreement) acquired all outstanding ordinary shares, par value British Pound Sterling 0.001 per share, of GW Pharmaceuticals plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement") (continued in footnote 2). F2: At the effective time of the Scheme of Arrangement, Scheme Shareholders (as defined in the Scheme of Arrangement) became entitled to receive for each Scheme Share (as defined in the Scheme of Arrangement) held by them an amount equal to $16.66 2/3 in cash plus 0.010030 ordinary shares, nominal value $0.0001 per share, of Jazz ("Jazz ordinary shares"). The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 15, 2021.
Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2022-03-15	Direct	Reported balance After 2021-05-05 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2021-05-05 · Disposition to issuer · Disposed 17,508 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration.
Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $10.61 · Expires 2025-06-24	Direct	Reported balance After 2021-05-05 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2021-05-05 · Disposition to issuer · Disposed 75,864 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration.
Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $3.72 · Expires 2026-02-15	Direct	Reported balance After 2021-05-05 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2021-05-05 · Disposition to issuer · Disposed 213,240 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration.
Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $9.81 · Expires 2027-01-06	Direct	Reported balance After 2021-05-05 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2021-05-05 · Disposition to issuer · Disposed 142,344 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration.
Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $9.61 · Expires 2028-02-26	Direct	Reported balance After 2021-05-05 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2021-05-05 · Disposition to issuer · Disposed 147,624 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration.
Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $14.33 · Expires 2029-03-01	Direct	Reported balance After 2021-05-05 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2021-05-05 · Disposition to issuer · Disposed 119,472 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration.
Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $14.65 · Expires 2029-06-14	Direct	Reported balance After 2021-05-05 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2021-05-05 · Disposition to issuer · Disposed 30,936 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration.
Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2021-05-05 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2021-05-05 · Disposition to issuer · Disposed 22,440 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5: These stock options were granted with automatic vesting on exercisable date.
Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2021-05-05 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2021-05-05 · Disposition to issuer · Disposed 34,008 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5: These stock options were granted with automatic vesting on exercisable date.
Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2021-05-05 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2021-05-05 · Disposition to issuer · Disposed 226,752 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5: These stock options were granted with automatic vesting on exercisable date.
Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2021-05-05 transaction · row 14 Instrument identity requires review; Table II rows are not merged. 1 source row Row 14 · 2021-05-05 · Disposition to issuer · Disposed 12,492 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5: These stock options were granted with automatic vesting on exercisable date.
Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2021-05-05 transaction · row 15 Instrument identity requires review; Table II rows are not merged. 1 source row Row 15 · 2021-05-05 · Disposition to issuer · Disposed 55,488 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5: These stock options were granted with automatic vesting on exercisable date.
Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2021-05-05 transaction · row 16 Instrument identity requires review; Table II rows are not merged. 1 source row Row 16 · 2021-05-05 · Disposition to issuer · Disposed 287,904 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5: These stock options were granted with automatic vesting on exercisable date.
Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2021-05-05 transaction · row 17 Instrument identity requires review; Table II rows are not merged. 1 source row Row 17 · 2021-05-05 · Disposition to issuer · Disposed 479,844 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F5: These stock options were granted with automatic vesting on exercisable date.
Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2021-05-05 transaction · row 18 Instrument identity requires review; Table II rows are not merged. 1 source row Row 18 · 2021-05-05 · Disposition to issuer · Disposed 164,496 · Balance 0 F4: Pursuant to the Transaction Agreement, one-third of these share options vested and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration, and the remaining two-thirds were converted into an option to acquire Jazz ordinary shares (with any performance goals deemed fully satisfied), half of which will vest on March 2, 2022 and half of which will vest on March 2, 2023. F5: These stock options were granted with automatic vesting on exercisable date.
Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2021-05-05 transaction · row 19 Instrument identity requires review; Table II rows are not merged. 1 source row Row 19 · 2021-05-05 · Disposition to issuer · Disposed 263,184 · Balance 0 F4: Pursuant to the Transaction Agreement, one-third of these share options vested and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration, and the remaining two-thirds were converted into an option to acquire Jazz ordinary shares (with any performance goals deemed fully satisfied), half of which will vest on March 2, 2022 and half of which will vest on March 2, 2023. F5: These stock options were granted with automatic vesting on exercisable date.

Filing footnotes · ownership attribution and instrument terms

F1: On May 5, 2021, Jazz Pharmaceuticals Public Limited Company, a public limited company incorporated in the Republic of Ireland ("Jazz"), Jazz Pharmaceuticals UK Holdings Limited, a private limited company incorporated in England and Wales and an indirect wholly owned subsidiary of Jazz ("Bidco") and the DR Nominee (as defined in the Transaction Agreement) acquired all outstanding ordinary shares, par value British Pound Sterling 0.001 per share, of GW Pharmaceuticals plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement") (continued in footnote 2).

F2: At the effective time of the Scheme of Arrangement, Scheme Shareholders (as defined in the Scheme of Arrangement) became entitled to receive for each Scheme Share (as defined in the Scheme of Arrangement) held by them an amount equal to $16.66 2/3 in cash plus 0.010030 ordinary shares, nominal value $0.0001 per share, of Jazz ("Jazz ordinary shares"). The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 15, 2021.

F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration.

F4: Pursuant to the Transaction Agreement, one-third of these share options vested and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration, and the remaining two-thirds were converted into an option to acquire Jazz ordinary shares (with any performance goals deemed fully satisfied), half of which will vest on March 2, 2022 and half of which will vest on March 2, 2023.

F5: These stock options were granted with automatic vesting on exercisable date.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
February 26, 2021 Filed Mar 3, 2021 02:27 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Exercise / conversionOrdinary Shares	22,440	$0.00	$31.42	Disclosure SEC source: 0000899243-21-009215 · doc4.xml · nonDerivative · entry 1 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,445 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise of share options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. F2 · price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.39 U.S. Dollars as of February 26, 2021. Read SEC document
February 22, 2021 Filed Feb 24, 2021 23:49 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	GrantShare Options · Derivative	263,184	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899243-21-008093 · doc4.xml · derivative · entry 2 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 263,184 Underlying: Ordinary Shares · 263,184 shares Expires not disclosed F3 · security: Granted pursuant to the Issuer's Long-Term Incentive Plan. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.41 U.S. Dollars as of February 22, 2021. F4 · derivative.exercise_date: These share options will vest in four equal annual installments beginning on February 22, 2022 and be automatically exercised upon vesting F5 · derivative.exercise_date: Subject to accelerated vesting in connection with the closing of the transactions contemplated by the Transaction Agreement, dated as of February 3, 2021, by and among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW Pharmaceuticals plc. F4 · derivative.expiration_date: These share options will vest in four equal annual installments beginning on February 22, 2022 and be automatically exercised upon vesting F5 · derivative.expiration_date: Subject to accelerated vesting in connection with the closing of the transactions contemplated by the Transaction Agreement, dated as of February 3, 2021, by and among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW Pharmaceuticals plc. Read SEC document
February 22, 2021 Filed Feb 24, 2021 23:49 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	GrantShare Options · Derivative	164,496	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899243-21-008093 · doc4.xml · derivative · entry 1 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,496 Underlying: Ordinary Shares · 164,496 shares Expires not disclosed F1 · security: Granted pursuant to the Issuer's Long-Term Incentive Plan. These share options will vest and be automatically exercised on February 22, 2024 if certain performance conditions are satisfied. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.41 U.S. Dollars as of February 22, 2021. F1 · derivative.exercise_date: Granted pursuant to the Issuer's Long-Term Incentive Plan. These share options will vest and be automatically exercised on February 22, 2024 if certain performance conditions are satisfied. F5 · derivative.exercise_date: Subject to accelerated vesting in connection with the closing of the transactions contemplated by the Transaction Agreement, dated as of February 3, 2021, by and among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW Pharmaceuticals plc. F1 · derivative.expiration_date: Granted pursuant to the Issuer's Long-Term Incentive Plan. These share options will vest and be automatically exercised on February 22, 2024 if certain performance conditions are satisfied. F5 · derivative.expiration_date: Subject to accelerated vesting in connection with the closing of the transactions contemplated by the Transaction Agreement, dated as of February 3, 2021, by and among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW Pharmaceuticals plc. Read SEC document
December 31, 2020 Filed Jan 7, 2021 02:01 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	GiftOrdinary Shares	456,048	$0.00	$0.00	Disclosure SEC source: 0000899243-21-000774 · doc4.xml · nonDerivative · entry 2 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Justin D. Gover 2020 Irrevocable Trust dated December 14, 2020 Disclosed balance after: 456,048 F1 · kind: This transaction involved a gift of securities by the reporting person to Justin D. Gover 2020 Irrevocable Trust dated December 14, 2020. Members of the reporting person's immediate family are the sole beneficiaries of the trust. Read SEC document
December 31, 2020 Filed Jan 7, 2021 02:01 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	GiftOrdinary Shares	456,048	$0.00	$0.00	Disclosure SEC source: 0000899243-21-000774 · doc4.xml · nonDerivative · entry 1 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5 F1 · kind: This transaction involved a gift of securities by the reporting person to Justin D. Gover 2020 Irrevocable Trust dated December 14, 2020. Members of the reporting person's immediate family are the sole beneficiaries of the trust. Read SEC document
November 17, 2020 Filed Nov 18, 2020 02:00 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Exercise / conversionStock Options · Derivative	42,708	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899243-20-031340 · doc4.xml · derivative · entry 11 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,409 Underlying: Ordinary Shares · 42,708 shares Expires 2021-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.33 U.S. Dollars as of November 17, 2020. F1 · kind: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. Read SEC document
November 17, 2020 Filed Nov 18, 2020 02:00 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	SaleOrdinary Shares	42,708	$10.03	$428,361.24	Disclosure SEC source: 0000899243-20-031340 · doc4.xml · nonDerivative · entry 7 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 456,053 F3 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2020. F4 · shares: Represented by ADSs. F8 · price: The price reported in Column 4 is a weighted average price per ordinary share ($120.3923 per ADS). These shares were sold in multiple transactions at prices ranging from $120.00 per ADS (or $10.00 per ordinary share) to $120.85 per ADS (or $10.07 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
November 17, 2020 Filed Nov 18, 2020 02:00 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Exercise / conversionOrdinary Shares	42,708	$0.00	$55.52	Disclosure SEC source: 0000899243-20-031340 · doc4.xml · nonDerivative · entry 6 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 498,761 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. F6 · price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.32 U.S. Dollars as of November 16, 2020. Read SEC document
November 16, 2020 Filed Nov 18, 2020 02:00 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Exercise / conversionStock Options · Derivative	22,800	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899243-20-031340 · doc4.xml · derivative · entry 10 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,117 Underlying: Ordinary Shares · 22,800 shares Expires 2021-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.32 U.S. Dollars as of November 16, 2020. F1 · kind: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. Read SEC document
November 16, 2020 Filed Nov 18, 2020 02:00 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	SaleOrdinary Shares	22,800	$10.02	$228,456.00	Disclosure SEC source: 0000899243-20-031340 · doc4.xml · nonDerivative · entry 5 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 456,053 F3 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2020. F4 · shares: Represented by ADSs. F7 · price: The price reported in Column 4 is a weighted average price per ordinary share ($120.2065 per ADS). These shares were sold in multiple transactions at prices ranging from $120.00 per ADS (or $10.00 per ordinary share) to $120.49 per ADS (or $10.04 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
November 16, 2020 Filed Nov 18, 2020 02:00 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Exercise / conversionOrdinary Shares	22,800	$0.00	$29.64	Disclosure SEC source: 0000899243-20-031340 · doc4.xml · nonDerivative · entry 4 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 478,853 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. F6 · price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.32 U.S. Dollars as of November 16, 2020. Read SEC document
November 13, 2020 Filed Nov 18, 2020 02:00 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Exercise / conversionStock Options · Derivative	3,924	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899243-20-031340 · doc4.xml · derivative · entry 9 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10 Underlying: Ordinary Shares · 3,924 shares Expires 2021-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.32 U.S. Dollars as of November 13, 2020. F1 · kind: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. Read SEC document
November 13, 2020 Filed Nov 18, 2020 02:00 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Exercise / conversionStock Options · Derivative	39,060	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899243-20-031340 · doc4.xml · derivative · entry 8 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,917 Underlying: Ordinary Shares · 39,060 shares Expires 2021-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.32 U.S. Dollars as of November 13, 2020. F1 · kind: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. Read SEC document
November 13, 2020 Filed Nov 18, 2020 02:00 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	SaleOrdinary Shares	42,984	$10.01	$430,269.84	Disclosure SEC source: 0000899243-20-031340 · doc4.xml · nonDerivative · entry 3 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 456,053 F3 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2020. F4 · shares: Represented by ADSs. F5 · price: Converted from price per ADS. The price reported in Column 4 is a weighted average price per ordinary share ($120.1533 per ADS). These shares were sold in multiple transactions at prices ranging from $120.00 per ADS (or $10.00 per ordinary share) to $120.99 per ADS (or $10.08 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
November 13, 2020 Filed Nov 18, 2020 02:00 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Exercise / conversionOrdinary Shares	3,924	$0.00	$5.10	Disclosure SEC source: 0000899243-20-031340 · doc4.xml · nonDerivative · entry 2 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 499,037 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. F2 · price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.32 U.S. Dollars as of November 13, 2020. Read SEC document
November 13, 2020 Filed Nov 18, 2020 02:00 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Exercise / conversionOrdinary Shares	39,060	$0.00	$50.78	Disclosure SEC source: 0000899243-20-031340 · doc4.xml · nonDerivative · entry 1 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 495,113 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. F2 · price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.32 U.S. Dollars as of November 13, 2020. Read SEC document
November 12, 2020 Filed Nov 13, 2020 02:00 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Exercise / conversionStock Options · Derivative	27,591	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899243-20-030883 · doc4.xml · derivative · entry 12 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,977 Underlying: Ordinary Shares · 27,591 shares Expires 2021-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.31 U.S. Dollars as of November 12, 2020. F1 · kind: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. Read SEC document
November 12, 2020 Filed Nov 13, 2020 02:00 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Exercise / conversionStock Options · Derivative	13,917	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899243-20-030883 · doc4.xml · derivative · entry 11 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 13,917 shares Expires 2021-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.31 U.S. Dollars as of November 12, 2020. F1 · kind: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. Read SEC document
November 12, 2020 Filed Nov 13, 2020 02:00 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Exercise / conversionStock Options · Derivative	22,800	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899243-20-030883 · doc4.xml · derivative · entry 10 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,934 Underlying: Ordinary Shares · 22,800 shares Expires 2021-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.31 U.S. Dollars as of November 12, 2020. F1 · kind: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. Read SEC document
November 12, 2020 Filed Nov 13, 2020 02:00 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	SaleOrdinary Shares	64,308	$10.01	$643,723.08	Disclosure SEC source: 0000899243-20-030883 · doc4.xml · nonDerivative · entry 7 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 456,053 F3 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2020. F4 · shares: Represented by ADSs. F7 · price: The price reported in Column 4 is a weighted average price per ordinary share ($120.1715 per ADS). These shares were sold in multiple transactions at prices ranging from $120.00 per ADS (or $10.00 per ordinary share) to $120.46 per ADS (or $10.04 per ordinary share), inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
November 12, 2020 Filed Nov 13, 2020 02:00 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Exercise / conversionOrdinary Shares	27,591	$0.00	$35.87	Disclosure SEC source: 0000899243-20-030883 · doc4.xml · nonDerivative · entry 6 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 520,361 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. F6 · price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.31 U.S. Dollars as of November 12, 2020. Read SEC document
November 12, 2020 Filed Nov 13, 2020 02:00 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Exercise / conversionOrdinary Shares	13,917	$0.00	$18.09	Disclosure SEC source: 0000899243-20-030883 · doc4.xml · nonDerivative · entry 5 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 492,770 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. F6 · price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.31 U.S. Dollars as of November 12, 2020. Read SEC document
November 12, 2020 Filed Nov 13, 2020 02:00 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Exercise / conversionOrdinary Shares	22,800	$0.00	$29.64	Disclosure SEC source: 0000899243-20-030883 · doc4.xml · nonDerivative · entry 4 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 478,853 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. F6 · price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.31 U.S. Dollars as of November 12, 2020. Read SEC document
November 09, 2020 Filed Nov 13, 2020 02:00 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Exercise / conversionStock Options · Derivative	3,600	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899243-20-030883 · doc4.xml · derivative · entry 9 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,917 Underlying: Ordinary Shares · 3,600 shares Expires 2021-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.32 U.S. Dollars as of November 9, 2020. F1 · kind: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. Read SEC document
November 09, 2020 Filed Nov 13, 2020 02:00 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Exercise / conversionStock Options · Derivative	3,600	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899243-20-030883 · doc4.xml · derivative · entry 8 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,734 Underlying: Ordinary Shares · 3,600 shares Expires 2021-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.32 U.S. Dollars as of November 9, 2020. F1 · kind: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. Read SEC document
November 09, 2020 Filed Nov 13, 2020 02:00 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	SaleOrdinary Shares	7,200	$10.00	$72,000.00	Disclosure SEC source: 0000899243-20-030883 · doc4.xml · nonDerivative · entry 3 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 456,053 F3 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2020. F4 · shares: Represented by ADSs. F5 · price: The price reported in Column 4 is a price per ordinary share converted from price per ADS. Read SEC document
November 09, 2020 Filed Nov 13, 2020 02:00 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Exercise / conversionOrdinary Shares	3,600	$0.00	$4.68	Disclosure SEC source: 0000899243-20-030883 · doc4.xml · nonDerivative · entry 2 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 463,253 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. F2 · price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.32 U.S. Dollars as of November 9, 2020. Read SEC document
November 09, 2020 Filed Nov 13, 2020 02:00 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Exercise / conversionOrdinary Shares	3,600	$0.00	$4.68	Disclosure SEC source: 0000899243-20-030883 · doc4.xml · nonDerivative · entry 1 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 459,653 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. F2 · price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.32 U.S. Dollars as of November 9, 2020. Read SEC document
June 15, 2020 Filed Jun 18, 2020 00:00 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Exercise / conversionStock Options · Derivative	4,164	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899243-20-016919 · doc4.xml · derivative · entry 3 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 4,164 shares Expires 2020-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.25 U.S. Dollars as of June 15, 2020. F1 · kind: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. Read SEC document
June 15, 2020 Filed Jun 18, 2020 00:00 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Tax withholdingOrdinary Shares	2,076	$10.23	$21,237.48	Disclosure SEC source: 0000899243-20-016919 · doc4.xml · nonDerivative · entry 2 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 456,053 F4 · kind: Mandatory withhold to cover vested RSU style share options. F5 · shares: Represented by ADS. F6 · price: The price reported is price per ordinary share converted from price per ADS. Read SEC document
June 15, 2020 Filed Jun 18, 2020 00:00 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Exercise / conversionOrdinary Shares	4,164	$0.00	$5.41	Disclosure SEC source: 0000899243-20-016919 · doc4.xml · nonDerivative · entry 1 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 458,129 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. F2 · price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.25 U.S. Dollars as of June 15, 2020. F3 · balance_after: Column 5 of Table I of the reporting person's form 4 filed with the SEC on March 4, 2020 includes 112,548 ordinary shares underlying RSU style share options pursuant to the Issuer's Long-Term Incentive Plan, including (i) 44,880 ordinary shares vesting automatically in two equal installments on February 26, 2021 and 2022, (ii) 51,012 ordinary shares vesting automatically in three equal installments on March 1, 2021, 2022, and 2023, and (iii) 16,656 ordinary shares vesting automatically in four equal installments on June 14, 2020, 2021, 2022, and 2023. These ordinary shares have been excluded from Column 5 of this form 4 and will be reported as each tranche is vested and automatically exercised. Read SEC document
June 04, 2020 Filed Jun 9, 2020 00:02 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	GrantShare Options · Derivative	287,904	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899243-20-015693 · doc4.xml · derivative · entry 2 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,904 Underlying: Ordinary Shares · 287,904 shares Expires not disclosed F2 · security: Granted pursuant to the Issuer's Long-Term Incentive Plan. F3 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.26 U.S. Dollars as of June 4, 2020. F4 · derivative.exercise_date: These share options will vest in four equal annual installments beginning on June 4, 2021 and be automatically exercised upon vesting. F4 · derivative.expiration_date: These share options will vest in four equal annual installments beginning on June 4, 2021 and be automatically exercised upon vesting. Read SEC document
June 04, 2020 Filed Jun 9, 2020 00:02 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	GrantShare Options · Derivative	479.844	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899243-20-015693 · doc4.xml · derivative · entry 1 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 479.844 Underlying: Ordinary Shares · 479.844 shares Expires not disclosed F1 · security: Granted pursuant to the Issuer's Long-Term Incentive Plan. These share options will vest and be automatically exercised on June 4, 2023 if certain performance conditions are satisfied. F3 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.26 U.S. Dollars as of June 4, 2020. F1 · derivative.exercise_date: Granted pursuant to the Issuer's Long-Term Incentive Plan. These share options will vest and be automatically exercised on June 4, 2023 if certain performance conditions are satisfied. F1 · derivative.expiration_date: Granted pursuant to the Issuer's Long-Term Incentive Plan. These share options will vest and be automatically exercised on June 4, 2023 if certain performance conditions are satisfied. Read SEC document
March 02, 2020 Filed Mar 4, 2020 23:01 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Exercise / conversionStock Options · Derivative	17,510	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899243-20-006995 · doc4.xml · derivative · entry 6 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7 Underlying: Ordinary Shares · 17,510 shares Expires 2020-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.28 U.S. Dollars as of March 2, 2020. F1 · kind: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. Read SEC document
March 02, 2020 Filed Mar 4, 2020 23:01 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Exercise / conversionStock Options · Derivative	30,334	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899243-20-006995 · doc4.xml · derivative · entry 5 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 30,334 shares Expires 2020-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.28 U.S. Dollars as of March 2, 2020. F1 · kind: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. Read SEC document
March 02, 2020 Filed Mar 4, 2020 23:01 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	SaleOrdinary Shares	8,400	$8.40	$70,560.00	Disclosure SEC source: 0000899243-20-006995 · doc4.xml · nonDerivative · entry 4 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 566,513 F3 · kind: Automatic sale to cover vested restricted stock units that have been previously reported in Column 5 of Table I. F4 · shares: Represented by ADSs. F6 · price: The price reported is price per ordinary share converted from price per ADS. Read SEC document
March 02, 2020 Filed Mar 4, 2020 23:01 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	SaleOrdinary Shares	24,456	$8.31	$203,229.36	Disclosure SEC source: 0000899243-20-006995 · doc4.xml · nonDerivative · entry 3 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 574,913 F2 · kind: Sale to cover exercise of stock options expiring on March 15, 2020. F4 · shares: Represented by ADSs. F6 · price: The price reported is price per ordinary share converted from price per ADS. Read SEC document
March 02, 2020 Filed Mar 4, 2020 23:01 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Exercise / conversionOrdinary Shares	17,510	$0.00	$22.76	Disclosure SEC source: 0000899243-20-006995 · doc4.xml · nonDerivative · entry 2 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 599,369 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. F5 · price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.28 U.S. Dollars as of March 2, 2020. Read SEC document
March 02, 2020 Filed Mar 4, 2020 23:01 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Exercise / conversionOrdinary Shares	30,334	$0.00	$39.43	Disclosure SEC source: 0000899243-20-006995 · doc4.xml · nonDerivative · entry 1 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 581,859 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. F5 · price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.28 U.S. Dollars as of March 2, 2020. Read SEC document
February 26, 2020 Filed Feb 28, 2020 23:02 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	SaleOrdinary Shares	876	$9.21	$8,067.96	Disclosure SEC source: 0000899243-20-006328 · doc4.xml · nonDerivative · entry 3 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 551,525 F1 · kind: Automatic sale of vested restricted stock units that have been previously reported in Column 5 of Table I. F2 · shares: Represented by American Depositary Shares of the Issuer ("ADS"). Each ADS represents twelve ordinary shares of the Issuer. F3 · price: The price reported is price per ordinary share converted from price per ADS. Read SEC document
February 26, 2020 Filed Feb 28, 2020 23:02 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	SaleOrdinary Shares	1,644	$9.17	$15,075.48	Disclosure SEC source: 0000899243-20-006328 · doc4.xml · nonDerivative · entry 2 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 552,401 F1 · kind: Automatic sale of vested restricted stock units that have been previously reported in Column 5 of Table I. F2 · shares: Represented by American Depositary Shares of the Issuer ("ADS"). Each ADS represents twelve ordinary shares of the Issuer. F3 · price: The price reported is price per ordinary share converted from price per ADS. Read SEC document
February 26, 2020 Filed Feb 28, 2020 23:02 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	SaleOrdinary Shares	9,480	$9.01	$85,414.80	Disclosure SEC source: 0000899243-20-006328 · doc4.xml · nonDerivative · entry 1 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 554,045 F1 · kind: Automatic sale of vested restricted stock units that have been previously reported in Column 5 of Table I. F2 · shares: Represented by American Depositary Shares of the Issuer ("ADS"). Each ADS represents twelve ordinary shares of the Issuer. F3 · price: The price reported is price per ordinary share converted from price per ADS. Read SEC document
February 03, 2020 Filed Feb 5, 2020 22:00 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Exercise / conversionStock Options · Derivative	202,224	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899243-20-003296 · doc4.xml · derivative · entry 5 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7 Underlying: Ordinary Shares · 202,224 shares Expires 2020-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.30 U.S. Dollars as of February 3, 2020. F1 · kind: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. Read SEC document
February 03, 2020 Filed Feb 5, 2020 22:00 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	SaleOrdinary Shares	19,548	$9.71	$189,811.08	Disclosure SEC source: 0000899243-20-003296 · doc4.xml · nonDerivative · entry 4 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 563,525 F3 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 3, 2019. F4 · shares: Represented by ADSs. F7 · price: The price reported in Column 4 is a weighted average price per ordinary share ($116.54 per ADS). These share were sold in multiple transactions at prices ranging from $9.68 per ordinary share ($116.19 per ADS) to $9.76 per ordinary share ($117.07 per ADS), inclusive. The Reporting Person understands to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
February 03, 2020 Filed Feb 5, 2020 22:00 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	SaleOrdinary Shares	110,964	$9.63	$1,068,583.32	Disclosure SEC source: 0000899243-20-003296 · doc4.xml · nonDerivative · entry 3 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 583,073 F3 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 3, 2019. F4 · shares: Represented by ADSs. F6 · price: The price reported in Column 4 is a weighted average price per ordinary share ($115.52 per ADS). These share were sold in multiple transactions at prices ranging from $9.60 per ordinary share ($115.16 per ADS) to $9.68 per ordinary share ($116.14 per ADS), inclusive. The Reporting Person understands to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
February 03, 2020 Filed Feb 5, 2020 22:00 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	SaleOrdinary Shares	71,712	$9.57	$686,283.84	Disclosure SEC source: 0000899243-20-003296 · doc4.xml · nonDerivative · entry 2 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 694,037 F3 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 3, 2019. F4 · shares: Represented by ADSs. F5 · price: The price reported in Column 4 is a weighted average price per ordinary share ($114.85 per ADS). These share were sold in multiple transactions at prices ranging from $9.51 per ordinary share ($114.16 per ADS) to $9.60 per ordinary share ($115.15 per ADS), inclusive. The Reporting Person understands to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
February 03, 2020 Filed Feb 5, 2020 22:00 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Exercise / conversionOrdinary Shares	202,224	$0.00	$262.89	Disclosure SEC source: 0000899243-20-003296 · doc4.xml · nonDerivative · entry 1 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 765,749 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. F1 · shares: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. F2 · price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.30 U.S. Dollars as of February 3, 2020. Read SEC document
December 17, 2019 Filed Dec 19, 2019 22:02 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Exercise / conversionStock Options · Derivative	10,668	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000899243-19-029665 · doc4.xml · derivative · entry 3 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11 Underlying: Ordinary Shares · 10,668 shares Expires 2019-12-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.31 U.S. Dollars as of December 17, 2019. Read SEC document
December 17, 2019 Filed Dec 19, 2019 22:02 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	SaleOrdinary Shares	5,340	$9.17	$48,967.80	Disclosure SEC source: 0000899243-19-029665 · doc4.xml · nonDerivative · entry 2 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 563,525 F3 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 14, 2019. F4 · shares: Represented by ADSs. F5 · price: The price reported in Column 4 is a price per ordinary share converted from price per ADS. Read SEC document
December 17, 2019 Filed Dec 19, 2019 22:02 UTC	GW PHARMACEUTICALS PLC GWPH · Entity 139616	Exercise / conversionOrdinary Shares	10,668	$0.00	$13.87	Disclosure SEC source: 0000899243-19-029665 · doc4.xml · nonDerivative · entry 1 Gover Justin D. · CIK 0001754129 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 568,865 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Exercise of stock options. Following the exercise, these shares were converted into American Depositary Shares of the Issuer ("ADS"). Each ADS represents twelve ordinary shares of the Issuer. F2 · price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.31 U.S. Dollars as of December 17, 2019. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.